PAI-1 activity, but not fibrinogen or von Willebrand factor, is inversely retated to LDL particte size in type 2 diabetes

被引:6
作者
Mertens, Ilse [1 ]
Lemieux, Isabelle [2 ]
Verrijken, An [1 ]
Despres, Jean-Pierre [2 ]
Van Gaal, Luc F. [1 ]
机构
[1] Univ Antwerp Hosp, Fac Med, Dept Diabetol Metab & Clin Nutr, B-2650 Antwerp, Belgium
[2] Laval Hosp Res Ctr, Quebec Heart Inst, Ste Foy, PQ, Canada
关键词
fibrinogen; von Willebrand factor; plasminogen activator inhibitor-1; small LDL; visceral adiposity;
D O I
10.1002/dmrr.779
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Levels of fibrinogen, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) have been associated with small low-density lipoprotein (LDL) particles. However, it is not clear whether these associations are independent of visceral adiposity or other components of the metabolic syndrome such as triglycerides or insulin resistance. Methods Visceral adipose tissue (VAT; CT-scan), fibrinogen, von Willebrand factor antigen (vWF: Ag), PAI-1 activity and different metabolic parameters such as total cholesterol (chol), HDL-chol, triglycerides, insulin resistance (homeostasis model assessment; HOMA-IR) were determined in 41 women and 78 men with type 2 diabetes. LDL particle size was assessed by polyacrylamide gradient gel electrophoresis. Results PAI-1 activity was inversely related to LDL particle size after adjustment for age and body mass index (BMI) (r = -0.28; p = 0.006) or age and VAT (r = -0.26; p = 0.01), but not after adjustment for age and HOMA-IR (r = -0.15; p = 0.148) or age and triglycerides (r = -0.04; p = 0.679). in multiple regression analysis, LDL particle size did not independently determine PAI-1 activity levels. Fibrinogen and vWF: Ag did not seem to be related to LDL size. Conclusions PAI-1 activity levels, in contrast to fibrinogen and vWF:Ag, seem to be related to the small LDL phenotype in patients with type 2 diabetes. However, this relationship was not independent of insulin resistance or triglycerides. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 39 条
  • [21] Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta-analysis
    Peng, Xun
    Wang, Xia
    Fan, Mengge
    Zhao, Junyu
    Lin, Liao
    Liu, Ju
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (01)
  • [22] INFLUENCE OF HYPERINSULINEMIC - HYPOGLYCEMIC CLAMP ON INDUCED PLATELET AGGREGATION, ACTIVITY OF PHYSIOLOGICAL ANTICOAGULANTS AND VON WILLEBRAND FACTOR IN PATIENTS WITH TYPE I DIABETES
    Jarek-Martynowa, Iwona R.
    Martynov, Mikhail Y.
    Sarkisova, Karina G.
    Koksharova, Ekaterina O.
    Mishina, Ekaterina E.
    Yasamanova, Albina N.
    Shestakova, Marina V.
    [J]. DIABETES MELLITUS, 2018, 21 (02): : 84 - 91
  • [23] Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor
    Aso, Y
    Fujiwara, Y
    Tayama, K
    Takanashi, K
    Inukai, T
    Takemura, Y
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2001, 109 (04) : 210 - 216
  • [24] Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory
    Zhukov, O.
    Popov, J.
    Ramos, R.
    Vause, C.
    Ruden, S.
    Sferruzza, A.
    Dlott, J.
    Sahud, M.
    [J]. HAEMOPHILIA, 2009, 15 (03) : 788 - 796
  • [25] Association between high von Willebrand factor levels and the Thr789Ala VWF gene polymorphism but not with nephropathy in type 1 diabetes
    Lacquemant, C
    Gaucher, C
    Delorme, C
    Chatellier, G
    Gallois, Y
    Rodier, M
    Passa, P
    Balkau, B
    Mazurier, C
    Marre, M
    Froguel, P
    [J]. KIDNEY INTERNATIONAL, 2000, 57 (04) : 1437 - 1443
  • [26] Levels of von willebrand factor, insulin resistance syndrome and a common vWF gene polymorphism in noninsulin-dependent (type 2) diabetes mellitus
    Heywood, DM
    Mansfield, MW
    Grant, PJ
    [J]. DIABETIC MEDICINE, 1996, 13 (08) : 720 - 725
  • [27] Markers of Endothelial Dysfunction: E-selectin, Endothelin-1 and von Willebrand Factor in Patients with Coronary Heart Disease, Including in Combination with Type 2 Diabetes Mellitus
    Zhito, Alexey, V
    Iusupova, Alfia O.
    Privalova, Elena, V
    Khabarova, Natalia, V
    Belenkov, Yurii N.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (06) : 892 - 899
  • [28] Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers
    Szederjesi, Attila
    Baronciani, Luciano
    Budde, Ulrich
    Castaman, Giancarlo
    Colpani, Paola
    Lawrie, Andrew S.
    Liu, Yuan
    Montgomery, Robert
    Peyvandi, Flora
    Schneppenheim, Reinhard
    Patzke, Juergen
    Bodo, Imre
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) : 2513 - 2523
  • [29] Association between Von Willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, D-Dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus
    Domingueti, Caroline Pereira
    Fuzatto, Jessica A.
    Foscolo, Rodrigo B.
    Reis, Janice S.
    Dusse, Luci M.
    Carvalho, Maria das Gracas
    Gomes, Karina B.
    Fernandes, Ana Paula
    [J]. CLINICA CHIMICA ACTA, 2016, 459 : 1 - 4
  • [30] Dominant von Willebrand Disease Type 2M and 2U Are Variable Expressions of One Distinct Disease Entity Caused by Loss-of-Function Mutations in the A1 Domain of the von Willebrand Factor Gene
    Gadisseur, Alain
    van der Planken, Marc
    Schroyens, Wilfried
    Berneman, Zwi
    Michiels, Jan Jacques
    [J]. ACTA HAEMATOLOGICA, 2009, 121 (2-3) : 145 - 153